Effectiveness and safety of ivabradine in Chinese patients with chronic heart failure: an observational study
Jingmin Zhou,Yamei Xu,Zhaofen Zheng,Shuyang Zhang,Jiefu Yang,Yuhui Zhang,Baopeng Tang,Huiyuan Han,Qing Zhang,Fan Liu,Wenhui Ding,Caizhen Qian,Guohai Su,Xiaohui Liu,Yuansheng Shen,Bei Shi,Xiangqing Kong,Zhiming Ge,Ping Zhang,Xiaomei Guo,Hong Zhang,Yuemin Sun,Yugang Dong,Guosheng Fu,Lei Feng,Junbo Ge,the POSITIVE investigators
DOI: https://doi.org/10.1002/ehf2.14581
2024-01-11
ESC Heart Failure
Abstract:Aims A therapeutic strategy for chronic heart failure (HF) is to lower resting heart rate (HR). Ivabradine is a well‐known HR‐lowering agent, but limited prospective data exist regarding its use in Chinese patients. This study aimed to evaluate the effectiveness and safety of ivabradine in Chinese patients with chronic HF. Methods and results This multicentre, single‐arm, prospective, observational study enrolled Chinese patients with chronic HF. The primary outcome was change from baseline in HR at 1 and 6 months, measured by pulse counting. Effectiveness was also evaluated using laboratory tests, the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (CSS) and overall summary score (OSS), and New York Heart Association (NYHA) class. Treatment‐emergent adverse events (TEAEs) were assessed. A post hoc analysis examined the effectiveness and safety of ivabradine combined with an angiotensin receptor–neprilysin inhibitor (ARNI) or beta‐blocker. A total of 1003 patients were enrolled [mean age 54.4 ± 15.0 years, 773 male (77.1%), mean baseline HR 88.5 ± 11.3 b.p.m., mean blood pressure 115.7/74.4 ± 17.2/12.3 mmHg, mean left ventricular ejection fraction 30.9 ± 7.6%, NYHA Classes III and IV in 48.8% and 22.0% of patients, respectively]. HR decreased by a mean of 12.9 and 16.1 b.p.m. after 1 and 6 months, respectively (both P
cardiac & cardiovascular systems